| Primary |
| Systemic Candida |
16.8% |
| Candidiasis |
11.7% |
| Fungal Infection |
6.6% |
| Candida Infection |
5.8% |
| Hypertension |
5.8% |
| Sepsis |
5.8% |
| Pain |
5.1% |
| Evidence Based Treatment |
4.4% |
| Immunosuppression |
4.4% |
| Status Epilepticus |
4.4% |
| Abdominal Sepsis |
3.6% |
| Candida Sepsis |
3.6% |
| Abdominal Infection |
2.9% |
| Hyperlipidaemia |
2.9% |
| Pneumonia |
2.9% |
| Pneumonia Streptococcal |
2.9% |
| Prophylaxis Against Gastrointestinal Ulcer |
2.9% |
| Vulval Cellulitis |
2.9% |
| Acute Myeloid Leukaemia Recurrent |
2.2% |
| Antibiotic Therapy |
2.2% |
|
| Death |
16.4% |
| Anaphylactic Shock |
7.5% |
| Haemorrhage |
6.0% |
| Septic Shock |
6.0% |
| Hepatitis Cholestatic |
4.5% |
| Hypersensitivity |
4.5% |
| Hypotension |
4.5% |
| Lung Infection |
4.5% |
| Multi-organ Failure |
4.5% |
| Pneumonia |
4.5% |
| Rash |
4.5% |
| Rash Maculo-papular |
4.5% |
| Tachycardia |
4.5% |
| Thrombocytopenia |
4.5% |
| Tubulointerstitial Nephritis |
4.5% |
| Anaphylactic Reaction |
3.0% |
| Bronchospasm |
3.0% |
| Chest Pain |
3.0% |
| Cholestasis |
3.0% |
| Coma Hepatic |
3.0% |
|
| Secondary |
| Candidiasis |
9.5% |
| Sepsis |
9.5% |
| Evidence Based Treatment |
8.1% |
| Hypertension |
8.1% |
| Pain |
8.1% |
| Status Epilepticus |
8.1% |
| Abdominal Infection |
6.8% |
| Abdominal Sepsis |
6.8% |
| Pneumonia |
5.4% |
| Aspergillosis |
4.1% |
| Candida Infection |
4.1% |
| Systemic Candida |
4.1% |
| Antibiotic Prophylaxis |
2.7% |
| Cholangitis |
2.7% |
| Cholecystitis |
2.7% |
| Epilepsy |
2.7% |
| Septic Shock |
2.7% |
| Bronchopneumonia |
1.4% |
| Calcium Deficiency |
1.4% |
| Candida Sepsis |
1.4% |
|
| Activated Partial Thromboplastin Time Prolonged |
16.7% |
| Lung Infection |
12.5% |
| Erythema |
8.3% |
| Gamma-glutamyltransferase Increased |
8.3% |
| Tubulointerstitial Nephritis |
8.3% |
| Death |
4.2% |
| Hepatitis Cholestatic |
4.2% |
| Hypotension |
4.2% |
| Multi-organ Failure |
4.2% |
| Pain In Extremity |
4.2% |
| Pancreatitis Necrotising |
4.2% |
| Pulmonary Hypertension |
4.2% |
| Septic Shock |
4.2% |
| Thrombocytopenia |
4.2% |
| Thrombocytosis |
4.2% |
| Ventricular Fibrillation |
4.2% |
|
| Concomitant |
| Abdominal Infection |
12.1% |
| Candidiasis |
12.1% |
| Paroxysmal Nocturnal Haemoglobinuria |
12.1% |
| Bacterial Infection |
9.1% |
| Product Used For Unknown Indication |
9.1% |
| Antibiotic Therapy |
6.1% |
| Hiv Infection |
6.1% |
| Mediastinitis |
6.1% |
| Osteomyelitis |
6.1% |
| Sepsis |
6.1% |
| Anaemia |
3.0% |
| Candida Infection |
3.0% |
| Infection |
3.0% |
| Osteoporosis |
3.0% |
| Pneumonia |
3.0% |
|
| Death |
13.3% |
| Drug Ineffective |
13.3% |
| Pigmentation Disorder |
13.3% |
| Systemic Candida |
13.3% |
| Toxic Epidermal Necrolysis |
13.3% |
| Drug Interaction |
6.7% |
| Pancreatitis |
6.7% |
| Pathogen Resistance |
6.7% |
| Thrombocytopenia |
6.7% |
| Tracheal Ulcer |
6.7% |
|
